Dehydroepiandrosterone Therapy as Female Androgen Replacement

ABSTRACT

Dehydroepiandrosterone (DHEA) is an abundant circulating androgen precursor preferentially produced by the adrenal glands. DHEA has been shown to exert its effects via downstream conversion to sex steroid hormones, neuromodulation, improvement in endothelial cell function, and possibly by acting on a cell membrane-bound receptor. Low levels of circulating DHEA have been demonstrated in women with diminished libido and other symptoms of sexual dysfunction. DHEA deficiency has also been associated with various drugs, and endocrine, nonhormonal, and age-related disorders. DHEA supplementation has been shown to produce beneficial effects in women with adrenal insufficiency. However, DHEA supplementation in healthy euadrenal subjects (including premenopausal and postmenopausal women with androgen insufficiency) is controversial; studies have yielded conflicting results regarding its beneficial effects on sexual function, metabolism, and overall well-being. Further research is needed to better elucidate the efficacy and safety of DHEA supplementation for the treatment of androgen insufficiency in women.

KEYWORDS

Dehydroepiandrosterone (DHEA) - female sexual dysfunction - androgen insufficiency

REFERENCES

• 1 Guay A, Davis S. Testosterone insufficiency in women: fact or fiction?.  World J Urol. 2002;  20 106-110
• 2 Bachmann G, Bancroft J, Braunstein G et al.. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment.  Fertil Steril. 2002;  77 660-665
• 3 Davison S, Bell R, Donath S, Montalto J, Davis S. Androgen levels in adult females: changes with age, menopause and oophorectomy.  J Clin Endocrinol Metab. 2005;  90(7) 3847-3853
• 4 Guay A, Munarriz R, Jacobson J et al.. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: part A: serum androgen levels in women aged 20-49 with no complaints of sexual dysfunction.  Int J Impot Res. 2004;  16 112-120
• 5 Guay A, Munarriz R, Jacobson J et al.. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: part B: reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction.  Int J Impot Res. 2004;  16 121-129
• 6 Davis S, Davison S, Donath S, Bell R. Circulating androgen levels and self-reported sexual function in women.  JAMA. 2005;  294 91-96
• 7 Miller K. The androgen deficiency syndrome in women.  Endocrinol Rounds. 2002;  1 1-8
• 8 Shifren J. The role of androgens in female sexual dysfunction.  Mayo Clin Proc. 2004;  79(suppl) S19-S24
• 9 Davis S, McCloud P, Strauss B, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality.  Maturitas. 1995;  21 227-236
• 10 Arlt W, Callies F, Van Vlijmen J et al.. Dehydroepiandrosterone replacement in women with adrenal insufficiency.  N Engl J Med. 1999;  341(14) 1013-1020
• 11 Burger H. Androgen production in women.  Fertil Steril. 2002;  77(4) S3-S5
• 12 Hammer F, Subtil S, Lux P et al.. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies.  J Clin Endocrinol Metab. 2005;  90 3600-3605
• 13 Siiteri P. Editorial: The continuing saga of dehydroepiandrosterone (DHEA).  J Clin Endocrinol Metab. 2005;  90 3795-3796
• 14 Orentreich N, Brind J, Rizer R, Vogelman J. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood.  J Clin Endocrinol Metab. 1984;  59 551-555
• 15 Arlt W. Dehydroepiandrosterone and ageing.  Best Pract Res Clin Endocrinol Metab. 2004;  18(3) 363-380
• 16 Hornsby P. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline.  Ann NY Acad Sci. 1995;  774 29-46
• 17 Legrain S, Massien C, Lahlou N et al.. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects.  J Clin Endocrinol Metab. 2000;  85(9) 3208-3217
• 18 Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S.  Mech Ageing Dev. 2002;  123 1101-1106
• 19 Labrie F. Intracrinology.  Mol Cell Endocrinol. 1991;  78 C113-C118
• 20 Labrie F, Belanger A, Van L T, Labrie C, Simard J, Cusan L. DHEA and the intracrine function of androgens and estrogens in peripheral target tissue: its role during aging.  Steroids. 1998;  63 322-328
• 21 Labrie F, Luu-The V, Lin S X et al.. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease.  J Mol Endocrinol. 2000;  25 1-16
• 22 Leblanc M, Labrie C, Belanger A, Candas B, Labrie F. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey.  J Clin Endocrinol Metab. 2003;  88 4923-4302
• 23 Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.  J Neurosci. 1996;  16 1193-1202
• 24 Majewska M, Demirgoren S, Spivak C, London E. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor.  Brain Res. 1990;  526 143-146
• 25 Compagnone N, Mellon S. Dehydroepiandrosterone: a potential signaling molecule for neocortical organization during development.  Proc Natl Acad Sci USA. 1998;  95 4678-4683
• 26 Beaulieu E. Neurostéro, leur rôle dans le fonctionnement du cerveau: neurotrophicité, mémoire, vieillisment.  Bull Acad Natl Med. 2001;  185 349-372
• 27 Liu D, Dillon J. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Gα_i2,3 .  J Biol Chem. 2002;  277 21379-21388
• 28 Liu D, Dillon J. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor.  Steroids. 2004;  69 279-289
• 29 Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani A. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms.  Endocrinology. 2003;  144 3449-3455
• 30 Williams M, Ling S, Dawood T et al.. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of androgen and estrogen receptors.  J Clin Endocrinol Metab. 2002;  87 176-181
• 31 Zapata E, Ventura J, De la Cruz K et al.. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent.  FEBS J. 2005;  272(6) 1343-1353
• 32 Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly though antioxidant effect.  J Clin Endocrinol Metab. 2004;  89 3449-3454
• 33 Ten S, New M, Maclaren N. Clinical review 130: Addison's disease 2001.  J Clin Endocrinol Metab. 2001;  86(7) 2909-2922
• 34 Arlt W. Quality of life in Addison's disease-the case for DHEA replacement.  Clin Endocrinol (Oxf). 2002;  56 573-574
• 35 Miller K, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A. Androgen deficiency in women with hypopituitarism.  J Clin Endocrinol Metab. 2001;  86(2) 561-567
• 36 Johannsson G, Burman P, Wiren L et al.. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.  J Clin Endocrinol Metab. 2002;  87(5) 2046-2052
• 37 Seki M, Nomura K, Kanazawa M, Sawada T, Takaski K, Demura H. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.  Endocr Relat Cancer. 1999;  6(4) 529-533
• 38 Deuschle M, Lecei O, Stalla G et al.. Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus-pituitary-adrenal system in healthy humans.  Neuropsychopharmacology.. 2003;  28 379-383
• 39 Gebre-Medhin G, Husebye E, Mallmin H et al.. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease.  Clin Endocrinol (Oxf). 2000;  52 775-780
• 40 Lovås K, Loge J, Husebye E. Subjective health status in Norwegian patients with Addison's disease.  Clin Endocrinol (Oxf). 2002;  56 581-588
• 41 Dhatariya K, Bigelow M, Nair K. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women.  Diabetes. 2005;  54(3) 765-769
• 42 Callies F, Fassnacht M, Van Vlijmen J et al.. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity.  J Clin Endocrinol Metab. 2001;  86(5) 1968-1972
• 43 Morales A, Nolan J, Nelson C, Yen S. Effects of replacement doses of dehydroepiandrosterone in men and women of advancing age.  J Clin Endocrinol Metab. 1994;  78 1360-1367
• 44 Van Niekerk J, Huppert F, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation.  Psychoneuroendocrinology. 2001;  26 591-612
• 45 Baulieu E, Thomas G, Legrain S et al.. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue.  Proc Natl Acad Sci USA. 2000;  97 4279-4284
• 46 Percheron G, Hogrel J, Denot-Ledunois S et al.. Effect of 1-year oral administration of dehydroepiandrosterone to 60 to 80 year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial.  Arch Intern Med. 2003;  163 720-727
• 47 Barnhart K, Freeman E, Grisso J et al.. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid perameters, and health-related quality of life.  J Clin Endocrinol Metab. 1999;  84(11) 3896-3902
• 48 Lasco A, Frisina N, Morabito N et al.. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women.  Eur J Endocrinol. 2001;  145 457-461
• 49 Casson P, Faquin L, Stentz F et al.. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women.  Fertil Steril. 1995;  63(5) 1027-1031
• 50 Villareal D, Holloszy J. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial.  JAMA. 2004;  292(18) 2243-2248
• 51 Kawano H, Yasue H, Kitagawa A et al.. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men.  J Clin Endocrinol Metab. 2003;  88(7) 3190-3195
• 52 Morales A, Haubrich R, Hwang J, Asakura H, Yen S. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.  Clin Endocrinol (Oxf). 1998;  49 421-432
• 53 Casson P, Santoro N, Elkind-Hirsch K et al.. Postmenopausal dehydroepiandrosterone administration increases insulin-like growth factor-1 and decreases high-density lipoprotein: A six-month trial.  Fertil Steril. 1998;  70(1) 107-110
• 54 Villareal D, Hooloszy J, Kohrt W. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men.  Clin Endocrinol (Oxf). 2000;  53 561-568
• 55 Tchernof A, Labrie F. Dehydroepiandrosterone, obesity, and cardiovascular disease risk: a review of human studies.  Eur J Endocrinol. 2004;  151(1) 1-14
• 56 Schmidt P, Daly R, Bloch M et al.. Dehydroepiandrosterone monotherapy in midlife-onset of major and minor depression.  Arch Gen Psychiatry. 2005;  62(2) 154-162
• 57 Bloch M, Schmidt P, Danaceau M, Adams L, Rubinow D. Dehydroepiandrosterone treatment of midlife dysthymia.  Biol Psychiatry. 1999;  45 1533-1541
• 57a Wolkowitz O, Kramer J, Resus V et al.. DHEA treatment of Alzheimer' disease: a randomized, double-blind, placebo-controlled study.  Neurology. 2003;  60 1071-1076
• 58 Chang D, Lan J, Lin H, Luo S. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2002;  46 2924-2927
• 59 Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone.  J Steroid Biochem Mol Biol. 2003;  85 469-472
• 60 Meikle A, Dorchuk R, Araneo B et al.. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells.  J Steroid Biochem Mol Biol. 1992;  42 293-304
• 61 Tsuji K, Furutama D, Tagami M, Oshawa N. Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: Possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy.  Life Sci. 1999;  65(1) 17-26
• 62 Davis S. Syndromes of hyperandrogenism in women.  Aust Fam Physician. 1999;  28(5) 447-451
• 63 Vryonidou A, Papatheodorou A, Tavridou A et al.. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2005;  90(5) 2740-2746
• 64 Arnaldi G, Angeli A, Atkinson A et al.. Diagnosis and complications of Cushing's syndrome: a consensus statement.  J Clin Endocrinol Metab. 2003;  88(12) 5593-5602
• 65 Sulcova J, Hill M, Hampl R, Starka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulfate in normal subjects.  J Endocrinol. 1997;  154 57-62
• 66 Labrie F, Belanger A, Cusan L, Gomez J, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.  J Clin Endocrinol Metab. 1997;  82 2396-2402
• 67 Maccario M, Mazza E, Ramunni J et al.. Relationships between dehydroepiandrosterone-sulfate and anthropometric, metabolic and hormonal variables in a large cohort of obese women.  Clin Endocrinol (Oxf). 1999;  50 595-600
• 68 Lasley B, Santoro N, Randolf J et al.. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity.  J Clin Endocrinol Metab. 2002;  87 3760-3767
• 69 Wiegratz I, Kutschera E, Lee J et al.. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.  Contraception. 2003;  67(1) 25-32
• 70 Meston C, Heiman J. Acute dehydroepiandrosterone effects on sexual arousal in premenopausal women.  J Sex Marital Ther. 2002;  28 53-60
• 71 Hackbert L, Heiman J. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women.  J Womens Health Gend Based Med. 2002;  11(2) 155-162
• 72 Buvat J. Androgen therapy with dehydroepiandrosterone.  World J Urol. 2003;  21 346-355
• 73 Guay A. Decreased testosterone in regularly menstruating women with decreased libido: a clinical observation.  J Sex Marital Ther. 2001;  27(5) 513-519
• 74 Munarriz R, Talakoub L, Flaherty E et al.. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire results.  J Sex Marital Ther. 2002;  28(suppl 1) 165-173
• 75 Stomati M, Monteleone P, Casarosa E et al.. Six-month oral hedydroepiandrosterone supplementation in early and late postmenopause.  Gynecol Endocrinol. 2000;  14 342-363
• 76 Stomati M, Rubino S, Spinetti A et al.. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women.  Gynecol Endocrinol. 1999;  13 15-25
• 77 Genazzani A, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani A. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.  Fertil Steril. 2003;  80 1495-1501
• 78 Chen F, Knecht K, Birzin E et al.. Direct agonist/antagonist function of dehydroepiandrosterone (DHEA).  Endocrinology. 2005;  146 4568-4576
• 79 Dhatariya K, Nair K. Dehydroepiandrosterone: is there a role for replacement?.  Mayo Clin Proc. 2003;  78 1257-1273
• 80 Davison S, Davis S. Androgens in women.  J Steroid Biochem Mol Biol. 2003;  85 363-366
• 81 Labrie F, Diamond P, Cusan L, Gomez J, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.  J Clin Endocrinol Metab. 1997;  82(11) 3498-3505
• 82 Grumbach M M, Conte F A. Disorders of sex differentiation. In: Wilson J, Foster D, Kronenberg H, Larsen PR Williams Textbook of Endocrinology. 9th ed. New York; WB Saunders 1998